SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Syros Pharmaceuticals, Inc. (SYRS) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+8334900%).
- 分析师共识目标价 $16.67 (+8334900% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 35/100 其中 1/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — SYRS
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-5.81
每股账面价值$0.00
每股营收$0.35
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$16.67 (+8334900%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2014 |
$-54.25 |
$0.00 |
$-13.43M |
- |
| 2015 |
$-120.45 |
$317K |
$-29.82M |
-9406.3% |
| 2016 |
$-37.60 |
$317K |
$-47.74M |
-15060.9% |
| 2017 |
$-21.26 |
$1.1M |
$-54.01M |
-4905.5% |
| 2018 |
$-19.07 |
$2.05M |
$-62.28M |
-3038% |
| 2019 |
$-18.76 |
$1.98M |
$-75.44M |
-3806.2% |
| 2020 |
$-18.64 |
$15.09M |
$-85.83M |
-568.7% |
| 2021 |
$-14.47 |
$23.49M |
$-90.47M |
-385.2% |
| 2022 |
$-3.90 |
$14.88M |
$-49.3M |
-331.3% |
| 2023 |
$-5.81 |
$9.94M |
$-164.57M |
-1656.3% |
